EVOK Logo.jpg
Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update
June 08, 2022 08:30 ET | Evoke Pharma, Inc.
SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
EVOK Logo.jpg
Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported
May 23, 2022 07:00 ET | Evoke Pharma, Inc.
Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide Supports Safety...
EVOK Logo.jpg
Patient Experience Survey Reported Positive Findings for GIMOTI®
May 18, 2022 08:30 ET | Evoke Pharma, Inc.
SOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and...
EVOK Logo.jpg
Evoke Pharma to Present at H.C. Wainwright Global Investment Conference
May 17, 2022 08:30 ET | Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
EVOK Logo.jpg
Evoke Pharma Reports First Quarter 2022 Financial Results
May 10, 2022 16:05 ET | Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today...
EVOK Logo.jpg
Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022
May 03, 2022 08:30 ET | Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...
EVOK Logo.jpg
Evoke Pharma Granted FDA Market Exclusivity for GIMOTI®
April 26, 2022 08:30 ET | Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
EVOK Logo.jpg
Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List
April 19, 2022 08:30 ET | Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
EVOK Logo.jpg
Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape
March 10, 2022 08:30 ET | Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
EVOK Logo.jpg
Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
March 08, 2022 16:05 ET | Evoke Pharma, Inc.
Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare...